SCHEMBL5366175

SCHEMBL5366175

CC(C)(C)c1cc(C=C2C(=O)Nc3ccc(I)cc32)cc(I)c1OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.51
EGFR P00533 4/20 0.51
IGF1R P08069 1/20 0.49
MAPT P10636 3/20 0.47
RAF1 P04049 3/20 0.47
SIRT2 Q8IXJ6 3/20 0.47
APP P05067 2/20 0.47
MAP1LC3B Q9GZQ8 2/20 0.47
SIRT1 Q96EB6 2/20 0.47
SIRT3 Q9NTG7 2/20 0.47
SIRT5 Q9NXA8 2/20 0.47
NTRK1 P04629 1/20 0.47
ARAF P10398 1/20 0.47
PIM1 P11309 1/20 0.47
BRAF P15056 1/20 0.47
CSNK2A1 P68400 1/20 0.47
PIM3 Q86V86 1/20 0.47
MYOC Q99972 1/20 0.47
DYRK4 Q9NR20 1/20 0.47
MAP3K20 Q9NYL2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358336 0.91 ERBB2 (0.52) ERBB2EGFRIGF1RMAPTRAF1
SCHEMBL5377038 0.91 ERBB2 (0.61) ERBB2EGFRIGF1RMAPTRAF1
SCHEMBL5358813 0.88 ERBB2 (0.47) ERBB2EGFRIGF1RRAF1SIRT2
SCHEMBL5364381 0.86 ERBB2 (0.45) ERBB2EGFRIGF1RNTRK1MAOA
SCHEMBL5361442 0.85 ERBB2 (0.62) ERBB2EGFRIGF1RMAPTRAF1
SCHEMBL5358782 0.83 ERBB2 (0.49) ERBB2EGFRIGF1RMAPTRAF1
SCHEMBL5358637 0.81 ERBB2 (0.51) ERBB2EGFRIGF1RRAF1SIRT2
SCHEMBL5361618 0.81 ERBB2 (0.48) ERBB2EGFRIGF1RMAPTRAF1
SCHEMBL5376628 0.80 AR (0.47) ERBB2EGFRIGF1RMEN1ALOX15
SCHEMBL5361957 0.79 ERBB2 (0.48) ERBB2EGFRIGF1RNTRK1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885IGF1R 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.